OmniAb (OABI) to Release Quarterly Earnings on Thursday

OmniAb (NASDAQ:OABI) will be issuing its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

OmniAb (NASDAQ:OABI) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. OmniAb had a negative return on equity of 15.41% and a negative net margin of 148.16%. The business had revenue of $4.82 million for the quarter, compared to analyst estimates of $6.94 million. On average, analysts expect OmniAb to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OmniAb Stock Down 2.5 %

Shares of NASDAQ:OABI opened at $4.59 on Wednesday. The company has a market cap of $537.61 million, a P/E ratio of -9.00 and a beta of -0.08. OmniAb has a 52 week low of $3.14 and a 52 week high of $6.72. The business has a fifty day simple moving average of $5.15 and a 200-day simple moving average of $5.29.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Benchmark restated a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a report on Friday, March 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $7.00 price target on shares of OmniAb in a report on Thursday, March 21st. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of OmniAb in a report on Thursday, March 21st. Finally, Truist Financial restated a “buy” rating and set a $10.00 price objective on shares of OmniAb in a research report on Tuesday, March 26th.

Insiders Place Their Bets

In related news, CFO Kurt A. Gustafson sold 11,849 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $5.46, for a total value of $64,695.54. Following the completion of the transaction, the chief financial officer now directly owns 170,110 shares of the company’s stock, valued at approximately $928,800.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Matthew W. Foehr bought 225,000 shares of the stock in a transaction that occurred on Friday, March 22nd. The shares were purchased at an average cost of $5.19 per share, with a total value of $1,167,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,908,803 shares in the company, valued at $15,096,687.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kurt A. Gustafson sold 11,849 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $5.46, for a total transaction of $64,695.54. Following the sale, the chief financial officer now owns 170,110 shares of the company’s stock, valued at $928,800.60. The disclosure for this sale can be found here. 7.00% of the stock is owned by insiders.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.